MRTX849 for Colorectal Cancer

Phase-Based Progress Estimates
Colorectal Cancer+2 More
MRTX849 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new drug, MRTX849, to see if it is better than chemotherapy at treating colorectal cancer that has a KRAS G12C mutation.

Eligible Conditions
  • Colorectal Cancer
  • Metastatic Colorectal Cancer (CRC)
  • Colorectal Carcinoma

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Similar Trials

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: 30 months

30 months
Adverse Events
Duration of Response (DOR)
Objective Response Rate (ORR)
Overall Survival (OS)
Patient Reported Outcomes (PROs)
Progression-free Survival (PFS)
Quality of Life Assessment

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

Trial Design

2 Treatment Groups

1 of 2
MRTX849 + Cetuximab
1 of 2

Active Control

Experimental Treatment

420 Total Participants · 2 Treatment Groups

Primary Treatment: MRTX849 · No Placebo Group · Phase 3

MRTX849 + CetuximabExperimental Group · 2 Interventions: Cetuximab, MRTX849 · Intervention Types: Biological, Drug
mFOLFOX6 or FOLFIRIActiveComparator Group · 2 Interventions: mFOLFOX6 Regimen, FOLFIRI Regimen · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 30 months

Who is running the clinical trial?

Mirati Therapeutics Inc.Lead Sponsor
57 Previous Clinical Trials
6,038 Total Patients Enrolled
Andrew Chi, MD, Ph.DStudy DirectorMirati Therapeutics
Hirak Der-Torossian, MDStudy DirectorMirati Therapeutics
2 Previous Clinical Trials
517 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
This text is discussing a colorectal carcinoma that has a KRAS G12C mutation.
People who have advanced cancer that was first treated with a chemotherapy regimen including either oxaliplatin or irinotecan, and who then had a documented progression of their disease, may be eligible to receive treatment with Ramucirumab.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 22nd, 2021

Last Reviewed: November 1st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
How old are they?
What site did they apply to?
SCRI - Tennessee Oncology - Chattanooga - Memorial Plaza100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%